

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

Aliqopa (copanlisib)

Override(s)	Approval Duration
Prior Authorization	Initial therapy: 6 months Continuation therapy: 6 months

Medications
Aliqopa (copanlisib) vial for infusion

APPROVAL CRITERIA

Initial requests for Aliqopa (copanlisib) may be approved if the following criteria are met:

- I. Individual has a diagnosis of relapsed follicular lymphoma; **AND**
- II. Individual has received at least two prior systemic therapies; **AND**
- III. Individual has not had previous treatment with another PI3-kinase inhibitor previously (e.g. idelalisib (Zydelig)).

Continuation of treatment requests for Aliqopa (copanlisib) may be approved if the following criterion is met:

- I. Confirmation of continuing clinical benefit (e.g. complete response, partial response, or stable disease).

Requests for Aliqopa (copanlisib) may not be approved for the following:

- I. Individual is requesting for any other indication, including but not limited to when the criteria above have not been met; **OR**
- II. Repeat treatment after the development of disease progression or unacceptable toxicity.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2019. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed October 2, 2019.
3. Dreyling M, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. *Ann Oncol.* 2017 Sep 1; 28(9):2169-2178. <https://clinicaltrials.gov/ct2/show/NCT01660451> Accessed on October 5, 2019.
4. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
5. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.
6. NCCN Clinical Practice Guidelines in Oncology™. © 2019 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed October 2, 2019.
 - a. B-Cell Lymphomas. V5.2019. Revised September 23, 2019.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply. CRX-ALL-0486-20